DGAP-News: Biotest AG / Key word(s): PersonnelBiotest AG: Biotest Supervisory Board appoints new Management Board member 02.05.2022 / 09:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest Supervisory Board appoints new Management Board member Peter Janssen will succeed Dr G.
02.05.2022 - DGAP-News: Biotest AG / Key word(s): Personnel Biotest AG: Biotest Supervisory Board appoints new Management Board member 02.05.2022 / 09:00 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest Supervisory . Seite 1
- EBIT burdened by product mix, plasma costs and increased hygiene expenses
- Forecast for 2021 confirmed
May,
2021. The Biotest Group recorded revenue of € 120.0 million in the first quarter of 2021. This represents an increase of 22.8 % compared to revenue of € 97.7 million in the same period of the previous year.
In terms of revenue, Biotest closed a strong first quarter, which was characterised by a worldwide increase in demand for immunoglobulins while the pandemic situation remained difficult. In particular, sales of Intratect
(R), Biotest s standard immunoglobulin, were significantly higher than in the previous year. Furthermore, sales of other products, such as Haemoctin
(R) and Albumin, were also higher compared to the first quarter of 2020.